Monosialoganglioside-Containing Nanoliposomes Restore Endothelial Function Impaired by AL Amyloidosis Light Chain Proteins.

• Main Authors: Franco, Daniel A, Truran, Seth, Weissig, Volkmar, Guzman-Villanueva, Diana, Karamanova, Nina, Senapati, Subhadip, Burciu, Camelia, Ramirez-Alvarado, Marina, Blancas-Mejia, Luis M, Lindsay, Stuart, Hari, Parameswaran, Migrino, Raymond Q
• Other Authors: Univ Arizona, Coll Med
• Language: en
• Published: WILEY-BLACKWELL 2016
• Subjects: amyloid; endothelium; nanotechnology; oxidant stress
• Online Access: http://hdl.handle.net/10150/621716; http://arizona.openrepository.com/arizona/handle/10150/621716

Light chain amyloidosis (AL) is associated with high mortality, especially in patients with advanced cardiovascular involvement. It is caused by toxicity of misfolded light chain proteins (LC) in vascular, cardiac, and other tissues. There is no treatment to reverse LC tissue toxicity. We tested the hypothesis that nanoliposomes composed of monosialoganglioside, phosphatidylcholine, and cholesterol (GM1 ganglioside-containing nanoliposomes [NLGM1]) can protect against LC-induced human microvascular dysfunction and assess mechanisms behind the protective effect.